Important note

This AI stock analysis for hims is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

hims - AI Stock Analysis

Analysis generated June 19, 2024

Hims, Inc. is a telehealth company that provides prescription and over-the-counter drugs, health and wellness supplements, and other health-related products and services. The company primarily targets millennials and Generation Z, and focuses on areas such as hair loss, erectile dysfunction, skincare, and mental health.

Fundamental Analysis

Hims has shown robust growth both in quarterly and annual comparisons. The revenue for the last quarter was $278M, which is an increase of 12.79% compared to the preceding quarter and a significant 45.81% year-over-year increase. This substantial revenue uptick indicates the company’s strong market presence and ability to scale.

In terms of profitability, the net income for the last quarter was $11M. This marks an impressive growth of 793.82% from the previous quarter and 210.54% year-over-year. Such an extraordinary increase in net income demonstrates the company's improving cost efficiency and profitability.

The EBITDA for the last quarter was also $11M, showcasing an astonishing rise of 3,434.33% compared to the previous quarter and 203.31% compared to the same quarter last year. This metric highlights strong operational performance and robust cash flow generation capabilities.

However, it's worth mentioning that there have been several insider sales in the last couple of months, which might be interpreted as a bearish signal.

Technical Analysis

The recent performance of Hims' stock price shows a bullish trend. The current stock price stands at $24.79, which is a significant increase of 70.14% over the last month and an impressive 196.89% increase year-over-year, indicating a strong positive trend in both the short and long term.

Looking at the moving averages, the SMA10 is currently 23.67, up from the previous SMA10 of 23.27, indicating an upward trend in the stock's price movement.

The RSI is at 70, which places it in a neutral zone, yet on the verge of being overbought. This calls for caution, as an RSI above 70 typically indicates that a stock might be overvalued and due for a pullback.

Alternative Data Analysis

Hims has shown mixed signals across various alternative data metrics. Starting with job postings, they have 96 open positions, which is up by 32% in the last couple of months, indicating plans for growth and expansion.

However, the business outlook is down by 9%, raising concerns. Additionally, their website traffic has seen a considerable decline with an estimate of 610,000 visitors, down by 33% over the past few months, a worrisome metric that may indicate a reduction in customer acquisition.

Customer engagement is more encouraging, with 200,000 followers on Instagram, up by 8%, and 10,000 followers on Twitter, up by 28%. This suggests increasing interest in the company's brand and offerings.

Lastly, Hims has an AI score of 64 from AltIndex, signifying a buy signal when all metrics are consolidated.

Conclusion and Recommendation

Based on the fundamental, technical, and alternative data analyses, Hims appears to be a promising investment. Their revenue and net income growth, as well as outstanding EBITDA performance, are highly compelling. The bullish stock price trend and positive customer engagement signals further bolster the case for investment.

However, some caution is advised due to insider selling, a high RSI indicating potential overvaluation, and declining web traffic, which could signal future challenges in customer acquisition.

Overall, the strong growth signals and positive AI score of 64 imply that Hims is a buy, but investors should stay vigilant on potential downturns in market sentiment and operational performance.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.